|
|
 Previous Article | Table of Contents | Next Article 
Full Immunologic Reconstitution Following Nonconditioned Bone Marrow Transplantation for Canine X-Linked Severe Combined Immunodeficiency
Peter J. Felsburg,
Richard L. Somberg,
Brian J. Hartnett,
Steven F. Suter,
Paula S. Henthorn,
Peter F. Moore,
Kenneth I. Weinberg, and
Hans D. Ochs
From the Department of Clinical Studies, School of Veterinary Medicine, University of Pennsylvania, Philadelphia, PA; Department of Pathology, School of Veterinary Medicine, University of California, Davis; Division of Research Immunology, Children's Hospital Los Angeles, School of Medicine, University of Southern California, Los Angeles, CA; and Department of Pediatrics, School of Medicine, University of Washington, Seattle, WA.
Bone marrow transplantation in human X-linked severe combined immunodeficiency (XSCID) without pretransplant conditioning results in engraftment of donor T cells and reconstitution of T-cell function but engraftment of few, if any, donor B cells and poor reconstitution of humoral immune function. Since bone marrow transplantation remains the most effective treatment of XSCID patients, better strategies are necessary to achieve optimum long-term results. Canine XSCID, like human XSCID, is due to mutations in the common  chain (c) gene and has clinical and immunologic features identical to those of human XSCID, making it a true homolog of the human disease. We have successfully performed bone marrow transplantation in three XSCID dogs without pretransplant conditioning, using untreated bone marrow cells from mixed lymphocyte culture-nonreactive normal littermates. Unlike the experience in human XSCID patients, all three dogs engrafted both donor B and T cells and attained full reconstitution of immunologic function. Normal percentages of T cells and T-cell mitogenic responses were attained by 3 months posttransplant. CD3+ T cells after transplantation expressed the CD45RA isoform indicating that the cells were recent thymic emigrants derived from immature progenitors. Serum IgG levels were within normal range by 5 months posttransplant. Immunization with the T-dependent antigen, bacteriophage  X174, demonstrated normal antibody titers, immunologic memory, and class-switching. Polymerase chain reaction (PCR) analysis of the c locus showed that 100% of circulating T cells and 30% to 50% of circulating B cells were donor-derived. None of the dogs developed clinically evident graft-versus-host disease (GVHD). Thus, canine XSCID provides a model to determine the optimal conditions for bone marrow transplantation in human patients, and to develop and test strategies for somatic gene therapy.
Blood, Vol. 90 No. 8 (July 15), 1997:
pp. 3214-3221
© 1997 by The American Society of Hematology.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
M. H. Goldschmidt, J. S. Kennedy, D. R. Kennedy, H. Yuan, D. E. Holt, M. L. Casal, A. M. Traas, E. A. Mauldin, P. F. Moore, P. S. Henthorn, et al.
Severe Papillomavirus Infection Progressing to Metastatic Squamous Cell Carcinoma in Bone Marrow-Transplanted X-Linked SCID Dogs.
J. Virol.,
July 1, 2006;
80(13):
6621 - 6628.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Haddad, F. L. Deist, P. Aucouturier, M. Cavazzana-Calvo, S. Blanche, G. D. S. Basile, and A. Fischer
Long-Term Chimerism and B-Cell Function After Bone Marrow Transplantation in Patients With Severe Combined Immunodeficiency With B Cells: A Single-Center Study of 22 Patients
Blood,
October 15, 1999;
94(8):
2923 - 2930.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Storb, C. Yu, T. Barnett, J. L. Wagner, H. J. Deeg, R. A. Nash, H.-P. Kiem, P. McSweeney, K. Seidel, G. Georges, et al.
Stable Mixed Hematopoietic Chimerism in Dog Leukocyte Antigen-Identical Littermate Dogs Given Lymph Node Irradiation Before and Pharmacologic Immunosuppression After Marrow Transplantation
Blood,
August 1, 1999;
94(3):
1131 - 1136.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. L. Evans and R. A. Morgan
Genetic induction of immune tolerance to human clotting factor VIII in a mouse model for hemophilia A
PNAS,
May 12, 1998;
95(10):
5734 - 5739.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
